Physician profile
Peter Q Jiang
NPI 1427067024
$57,405.33
in general payments reported to CMS, 2019-2025
49 companies · $9,783 in 2025
The $9,783 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $9,564 · 2021: $550 · 2022: $8,583 · 2023: $16K · 2024: $12K · 2025: $9,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Travel and Lodging: $3,637 · Food and Beverage: $2,996 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,400 · Education: $470 · Grant: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,134.50 |
| Travel and Lodging | $3,637.01 |
| Food and Beverage | $2,996.03 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,400.00 |
| Education | $469.92 |
| Grant | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $10,493.98 | 2019-2025 | Imfinzi, Calquence, Truqap |
| Incyte Corporation | $7,424.05 | 2020-2025 | Monjuvi, Pemazyre |
| Glaxosmithkline, LLC. | $5,076.13 | 2020-2023 | Shingrix |
| Genentech USA, INC. | $4,852.05 | 2019-2023 | Columvi, Lunsumio, Polivy |
| Beigene USA, INC. | $4,558.50 | 2020-2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $3,994.63 | 2021-2024 | |
| Kite Pharma, INC. | $3,937.57 | 2021-2023 | |
| Eisai INC. | $3,311.60 | 2019-2023 | |
| Astellas Pharma US INC | $2,596.60 | 2023-2025 | Vyloy |
| Exelixis INC. | $1,556.99 | 2023-2024 | Cabometyx |
| Mirati Therapeutics, INC. | $1,500.24 | 2023-2024 | Krazati |
| Celgene Corporation | $1,255.41 | 2021-2024 | Pomalyst, Reblozyl |
| Janssen Scientific Affairs, LLC | $1,160.00 | 2022-2025 | Talvey |
| Geron Corporation | $780.00 | 2025 | Rytelo |
| Daiichi Sankyo INC. | $770.96 | 2020-2025 | Vanflyta, Injectafer |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $654.98 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Sobi, INC | $429.25 | 2023-2024 | |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Alexion Pharmaceuticals, INC. | $346.83 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $272.20 | 2023-2024 | Tavalisse, Rezlidhia |
| Novocure Gmbh | $250.00 | 2022 | |
| Abbvie INC. | $243.31 | 2021-2025 | |
| Genzyme Corporation | $154.73 | 2019-2021 | |
| Beone Medicines USA, INC. | $133.50 | 2025 | Tevimbra |
| Seagen INC. | $126.21 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $125.00 | 2019 | |
| Merck Sharp & Dohme LLC | $120.86 | 2019-2025 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $120.56 | 2020-2025 | |
| Comsort, INC | $100.00 | 2019 | |
| Amgen INC. | $90.09 | 2019-2022 | |
| Gilead Sciences, INC. | $89.91 | 2021-2025 | Trodelvy |
| Array Biopharma INC | $57.72 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Ipsen Biopharmaceuticals, INC | $57.63 | 2024-2025 | Onivyde |
| Pfizer INC. | $53.29 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.65 | 2019-2023 | |
| Emd Serono, INC. | $41.25 | 2023 | Mavenclad |
| Sirtex Medical INC | $40.31 | 2019 | |
| Terumo Bct, INC. | $36.36 | 2019 | |
| Adc Therapeutics America, INC. | $35.41 | 2021-2022 | |
| Heron Therapeutics, INC. | $27.14 | 2019-2022 | |
| Genmab U.S., INC. | $25.00 | 2025 | Epkinly |
| Deciphera Pharmaceuticals INC. | $18.71 | 2021 | |
| Jazz Pharmaceuticals INC. | $17.87 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $16.77 | 2023 | Libtayo |
| Lilly USA, LLC | $16.19 | 2025 | Verzenio, Jaypirca, Retevmo |
| Blueprint Medicines Corporation | $13.83 | 2022 | |
| Coherus Oncology, INC. | $13.42 | 2022 | |
| Puma Biotechnology, INC. | $11.64 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.